Acutaas Chemicals Q2 Results: Profit Up 71% to ₹123 Crore, Growth Guidance Raised to 30% (Oct 27, 2026)

The Acutaas Chemicals Q2 results, out on October 27, 2026, were the kind that make a stock run first and ask questions later. The Surat-based maker of pharmaceutical intermediates and speciality chemicals, which was called Ami Organics until its rename, reported consolidated revenue from operations of ₹436.9 crore for the July-September quarter, up 42.7% from ₹306.2 crore a year ago, according to its press release filed with NSE. Profit after tax rose 71.4% to ₹123.1 crore from ₹71.9 crore.

The market’s reply was quick. CNBC Awaaz (CNBC-TV18’s Hindi service) reported that the shares touched ₹3,739 on Tuesday against a previous close of ₹3,348, a gain of roughly 12% that took the stock to its high for the year.

Acutaas Chemicals Q2 results in numbers

Everything below is consolidated, for the quarter ended September 30, 2026 (Q2 FY27), compared with Q2 FY26 unless we say otherwise. The company reports in millions of rupees; we’ve converted to crore.

• Revenue from operations: ₹436.9 crore, up 42.7% year on year and up 32.5% from ₹329.7 crore in the June quarter.
• Gross margin: 62.1% of revenue, against 55.8% a year ago, an improvement the company puts at 637 basis points.
• EBITDA: ₹176.0 crore, up 84.6% from ₹95.3 crore.
• EBITDA margin: 40.3% of revenue, up from 31.1% a year ago and 34.3% in the June quarter.
• Profit after tax: ₹123.1 crore, up 71.4%, with a PAT margin of 28.2% against 23.5%.

One small wrinkle if you’re comparing headlines. CNBC Awaaz put net profit at ₹125.2 crore, up 73.9% from about ₹72 crore. That figure is profit attributable to the company’s owners, which in the results filing sits a little above total PAT because the minority shareholders’ share of the quarter was a loss. Both numbers tell the same story.

What drove the quarter

Executive chairman and MD Naresh Patel credited continued momentum in the pharmaceutical intermediates business. Speciality chemicals, the newer leg of the business, was softer and partly offset that growth, so this was very much a pharma-led quarter.

The margin jump is the bit we’d watch most closely. Revenue grew about 43%, but EBITDA grew about 85%, and the gross margin expansion explains much of the gap. A 40% EBITDA margin is very high for a chemicals company, and the June quarter’s 34.3% is a reminder that it moves around. Our explainer on EBITDA margin walks through why a jump like this deserves a second look.

Guidance goes up, and a new plant in Korea

Management raised its FY27 revenue growth guidance to around 30%, from 25% earlier, citing better revenue visibility and a strong order pipeline. It also lifted its EBITDA margin guidance to a 38-40% range.

The other headline was the inauguration of its South Korea manufacturing facility, which the company says came ahead of schedule. The plant is meant to make high-purity chemicals for photoresists, semiconductor packaging, etching and other chip-making uses. That’s the speciality chemicals bet: a slow segment today, with the company hoping semiconductors change that.

For the first half of FY27, revenue rose 49.3% to ₹766.6 crore, EBITDA nearly doubled (up 97.7%) to ₹289.0 crore, and PAT climbed 71.0% to ₹198.1 crore.

So where does that leave investors? The pharma intermediates engine is clearly firing. The open questions are whether margins can hold near the upper end of the new guidance, and how fast the Korea plant turns into revenue. Our checklist on how to analyse quarterly results is a good way to keep track over the next few quarters.

Disclaimer: This article is for information and education only and is not investment advice. Please do your own research or consult a SEBI-registered adviser before investing.